We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
Read MoreHide Full Article
Shares of Lexicon Pharmaceuticals (LXRX - Free Report) jumped 12% on Tuesday after the company announced that its heart failure therapy Inpefa (sotagliflozin) will be placed as a preferred product on pharmacy benefits manager (“PBM”) Express Scripts’ Medicare national formularies effective Nov 1, 2023.
Express Scripts will place Inpefa on its Premier Access and Premier Performance national formularies for Medicare patients. As a result of this placement, Express Scripts’ Medicare patients in specific plans will now be able to access Inpefa, thereby expanding the drug’s market reach.
Being a middleman between insurance companies, pharmacies, and drug manufacturers, PBMs like Express Scripts will be able to provide broader access and more comprehensive coverage for drugs placed on their plans as a preferred product.
Shares of Lexicon Pharmaceuticals have lost 41.4% year to date compared with the industry’s 19.3% decline.
Image Source: Zacks Investment Research
An oral SGLT inhibitor, Lexicon’s Inpefa received FDA approval earlier this year in May to reduce the risk of death and hospitalization in adults with either heart failure or those with type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors.
Per Lexicon, Inpefa is one of the three FDA-approved SGLT inhibitors to treat heart failure. The other two SGLT inhibitors are marketed by pharma giants AstraZeneca (AZN - Free Report) and Eli Lilly (LLY - Free Report) . AstraZeneca markets Farxiga (dapagliflozin), while Lilly markets Jardiance (empagliflozin). Lexicon is likely to face stiff competition from both these companies.
Both AstraZeneca’s Farxiga and Lilly’s Jardiance are blockbuster drugs and directly compete with each other in some indications, one of which is to treat heart failure. In first-half 2023, AstraZeneca generated $2.8 billion from Farxiga sales, a 39% rise from the year-ago period’s levels. Lilly added $1.25 billion from Jardiance sales, up 42% year over year during the same period.
Image: Bigstock
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
Shares of Lexicon Pharmaceuticals (LXRX - Free Report) jumped 12% on Tuesday after the company announced that its heart failure therapy Inpefa (sotagliflozin) will be placed as a preferred product on pharmacy benefits manager (“PBM”) Express Scripts’ Medicare national formularies effective Nov 1, 2023.
Express Scripts will place Inpefa on its Premier Access and Premier Performance national formularies for Medicare patients. As a result of this placement, Express Scripts’ Medicare patients in specific plans will now be able to access Inpefa, thereby expanding the drug’s market reach.
Being a middleman between insurance companies, pharmacies, and drug manufacturers, PBMs like Express Scripts will be able to provide broader access and more comprehensive coverage for drugs placed on their plans as a preferred product.
Shares of Lexicon Pharmaceuticals have lost 41.4% year to date compared with the industry’s 19.3% decline.
Image Source: Zacks Investment Research
An oral SGLT inhibitor, Lexicon’s Inpefa received FDA approval earlier this year in May to reduce the risk of death and hospitalization in adults with either heart failure or those with type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors.
Per Lexicon, Inpefa is one of the three FDA-approved SGLT inhibitors to treat heart failure. The other two SGLT inhibitors are marketed by pharma giants AstraZeneca (AZN - Free Report) and Eli Lilly (LLY - Free Report) . AstraZeneca markets Farxiga (dapagliflozin), while Lilly markets Jardiance (empagliflozin). Lexicon is likely to face stiff competition from both these companies.
Both AstraZeneca’s Farxiga and Lilly’s Jardiance are blockbuster drugs and directly compete with each other in some indications, one of which is to treat heart failure. In first-half 2023, AstraZeneca generated $2.8 billion from Farxiga sales, a 39% rise from the year-ago period’s levels. Lilly added $1.25 billion from Jardiance sales, up 42% year over year during the same period.
Lexicon Pharmaceuticals, Inc. Price
Lexicon Pharmaceuticals, Inc. price | Lexicon Pharmaceuticals, Inc. Quote
Zacks Rank
Lexicon currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.